<div><p>The proportion of infants with serum anti-capsular IgG antibody concentration ≥ 35µg/ml, a putative measure of protection against invasive pneumococcal disease, following vaccination with PCV-7. Vaccine was administered at 6,10 and 14 weeks of age or at 6,14 and 40 weeks of age. Antibody concentrations were assessed after the second and after the third dose in the series.</p> <p>PCV-7= 7-valent Pneumococcal Conjugate Vaccine, IgG = Immunoglobulin G.</p></div
The immunogenicity and impact on carriage of fewer doses of pneumococcal conjugate vaccine (PCV7) fo...
In a previous UK multi-center randomized study 278 children received three doses of 7-valent (PCV-7)...
In a previous UK multi-center randomized study 278 children received three doses of 7-valent (PCV-7)...
In this cohort study we compared IgG antibody levels between infants immunized with 7-valent CRM197-...
Despite immunisation, antibiotics and intensive care management, infection with We measured pneumoc...
The high cost of pneumococcal conjugate vaccine (PCV) and local epidemiological factors contributed ...
The aim was to identify an appropriate infant pneumococcal vaccination strategy for resource poor co...
The aim was to identify an appropriate infant pneumococcal vaccination strategy for resource poor co...
BACKGROUND: The high cost of pneumococcal conjugate vaccine (PCV) and local epidemiological factors ...
AbstractThe seven-valent pneumococcal conjugate vaccine (PCV7) has been introduced in most high-inco...
Preterm infants are at an increased risk of invasive pneumococcal disease infection and, additionall...
<p>The difference in the proportions in the vaccinated and control communities that achieved anti-pn...
We assessed the immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccin...
<p>*P value = 0.0009 before Holm's correction for multiple significance tests.</p><p>**P value = 0.0...
BackgroundThere are few studies about immunogenicity and safety of heptavalent pneumococcal-CRM197 c...
The immunogenicity and impact on carriage of fewer doses of pneumococcal conjugate vaccine (PCV7) fo...
In a previous UK multi-center randomized study 278 children received three doses of 7-valent (PCV-7)...
In a previous UK multi-center randomized study 278 children received three doses of 7-valent (PCV-7)...
In this cohort study we compared IgG antibody levels between infants immunized with 7-valent CRM197-...
Despite immunisation, antibiotics and intensive care management, infection with We measured pneumoc...
The high cost of pneumococcal conjugate vaccine (PCV) and local epidemiological factors contributed ...
The aim was to identify an appropriate infant pneumococcal vaccination strategy for resource poor co...
The aim was to identify an appropriate infant pneumococcal vaccination strategy for resource poor co...
BACKGROUND: The high cost of pneumococcal conjugate vaccine (PCV) and local epidemiological factors ...
AbstractThe seven-valent pneumococcal conjugate vaccine (PCV7) has been introduced in most high-inco...
Preterm infants are at an increased risk of invasive pneumococcal disease infection and, additionall...
<p>The difference in the proportions in the vaccinated and control communities that achieved anti-pn...
We assessed the immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccin...
<p>*P value = 0.0009 before Holm's correction for multiple significance tests.</p><p>**P value = 0.0...
BackgroundThere are few studies about immunogenicity and safety of heptavalent pneumococcal-CRM197 c...
The immunogenicity and impact on carriage of fewer doses of pneumococcal conjugate vaccine (PCV7) fo...
In a previous UK multi-center randomized study 278 children received three doses of 7-valent (PCV-7)...
In a previous UK multi-center randomized study 278 children received three doses of 7-valent (PCV-7)...